INTRODUCTION: The Li-Fraumeni Syndrome is caused by a germline TP53 mutation and is associated with a high risk of breast cancer at young ages. Basal (triple negative) breast cancers are now well recognised to be a typical sub-type of breast cancer developing in a large proportion of BRCA1 gene carriers. We considered whether a similar narrow sub-type of breast cancer was found in TP53 gene mutation carriers. OBJECTIVE: A hypothesis generating study to investigate whether there are specific breast tumour characteristics associated with germline TP53 mutations. METHODS: Pathological characteristics in 12 breast cancers arising in nine patients carrying pathogenic TP53 mutations were compared to a reference panel of 231 young onset breast tumours included in the POSH study. RESULTS: Patients carrying a TP53 mutation showed a significantly higher likelihood of developing a breast cancer with Human Epidermal growth factor Receptor (HER2) amplification (83%) when compared to the cohort of young onset breast cancer cases (16%); ER and PR status were equivalent between groups. CONCLUSION: These findings suggest that breast cancer developing on a background of an inherited TP53 mutation is highly likely to present with amplification of HER2.
INTRODUCTION: The Li-Fraumeni Syndrome is caused by a germline TP53 mutation and is associated with a high risk of breast cancer at young ages. Basal (triple negative) breast cancers are now well recognised to be a typical sub-type of breast cancer developing in a large proportion of BRCA1 gene carriers. We considered whether a similar narrow sub-type of breast cancer was found in TP53 gene mutation carriers. OBJECTIVE: A hypothesis generating study to investigate whether there are specific breast tumour characteristics associated with germline TP53 mutations. METHODS: Pathological characteristics in 12 breast cancers arising in nine patients carrying pathogenic TP53 mutations were compared to a reference panel of 231 young onset breast tumours included in the POSH study. RESULTS: Patients carrying a TP53 mutation showed a significantly higher likelihood of developing a breast cancer with Human Epidermal growth factor Receptor (HER2) amplification (83%) when compared to the cohort of young onset breast cancer cases (16%); ER and PR status were equivalent between groups. CONCLUSION: These findings suggest that breast cancer developing on a background of an inherited TP53 mutation is highly likely to present with amplification of HER2.
Authors: Brooke M Emerling; Jonathan B Hurov; George Poulogiannis; Kazumi S Tsukazawa; Rayman Choo-Wing; Gerburg M Wulf; Eric L Bell; Hye-Seok Shim; Katja A Lamia; Lucia E Rameh; Gary Bellinger; Atsuo T Sasaki; John M Asara; Xin Yuan; Andrea Bullock; Gina M Denicola; Jiaxi Song; Victoria Brown; Sabina Signoretti; Lewis C Cantley Journal: Cell Date: 2013-11-07 Impact factor: 41.582
Authors: Serena Masciari; Deborah A Dillon; Michelle Rath; Mark Robson; Jeffrey N Weitzel; Judith Balmana; Stephen B Gruber; James M Ford; David Euhus; Alexandra Lebensohn; Melinda Telli; Stephen M Pochebit; Georgios Lypas; Judy E Garber Journal: Breast Cancer Res Treat Date: 2012-03-04 Impact factor: 4.872
Authors: J J Bakhuizen; F B Hogervorst; M E Velthuizen; M W Ruijs; K van Engelen; T A van Os; J J Gille; M Collée; A M van den Ouweland; C J van Asperen; C M Kets; A R Mensenkamp; E M Leter; M J Blok; M M de Jong; M G Ausems Journal: Fam Cancer Date: 2019-04 Impact factor: 2.375
Authors: Katie M Marker; Valentina A Zavala; Tatiana Vidaurre; Paul C Lott; Jeannie Navarro Vásquez; Sandro Casavilca-Zambrano; Mónica Calderón; Julio E Abugattas; Henry L Gómez; Hugo A Fuentes; Ruddy Liendo Picoaga; Jose M Cotrina; Silvia P Neciosup; Carlos A Castañeda; Zaida Morante; Fernando Valencia; Javier Torres; Magdalena Echeverry; Mabel E Bohórquez; Guadalupe Polanco-Echeverry; Ana P Estrada-Florez; Silvia J Serrano-Gómez; Jenny A Carmona-Valencia; Isabel Alvarado-Cabrero; María Carolina Sanabria-Salas; Alejandro Velez; Jorge Donado; Sikai Song; Daniel Cherry; Lizeth I Tamayo; Scott Huntsman; Donglei Hu; Roberto Ruiz-Cordero; Ronald Balassanian; Elad Ziv; Jovanny Zabaleta; Luis Carvajal-Carmona; Laura Fejerman Journal: Cancer Res Date: 2020-04-03 Impact factor: 12.701
Authors: Michelle G Rath; Serena Masciari; Rebecca Gelman; Alexander Miron; Penelope Miron; Kathleen Foley; Andrea L Richardson; Ian E Krop; Sigitas J Verselis; Deborah A Dillon; Judy E Garber Journal: Breast Cancer Res Treat Date: 2013-04-12 Impact factor: 4.872